Business Wire Feed
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet more...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be presented more...
Diversified Healthcare Trust to Present at Nareit’s REITweek 2026 Investor Conference on Tuesday, June 2nd
NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced that President and Chief Executive Officer Chris Bilotto and Chief Financial Officer and Treasurer Matthew Brown will be presenting at Nareit’s REITweek 2026 Investor Conference in more...
Reimagine Care Expands AI-Enabled Virtual Oncology Model with Moffitt Cancer Center Following Strong Patient and Clinical Outcomes
Initial phase shows sustained patient engagement, reduced acute care utilization and a scalable approach to delivering continuous cancer care beyond the clinicNASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care today announced the expansion of its AI-enabled virtual oncology care more...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
ALAMEDA, Calif.--(BUSINESS WIRE)--#CRISPR--Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured clearance more...
Inovalon and Face Rock Enterprises Collaborate to Care for Tribal Health Organizations
Pairing Inovalon’s national-scale data and revenue cycle technology and Face Rock’s deep tribal health expertise to strengthen financial sustainability in underserved tribal communitiesBOWIE, Md.--(BUSINESS WIRE)--Inovalon, a leading provider of data and solutions empowering data-driven healthcare, more...
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
Strategic milestone delivers one of the most comprehensive and timely real-world views of community oncology, strengthening Ontada’s portfolio for biopharma partnersBOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, announced the integration more...
Aramark Healthcare+ Recognized by Modern Healthcare as One of the “Best Places to Work™ in Healthcare” for Third Consecutive Year
PHILADELPHIA--(BUSINESS WIRE)--Aramark Healthcare+ has been named to Modern Healthcare’s “Best Places to Work™ in Healthcare” list for 2026, marking the third consecutive year the organization has earned the recognition. Final rankings will be announced later more...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant’s leadership in comprehensive molecular profiling and advances more...
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
HTX-001 is a first-in-class antisense oligonucleotide designed to downregulate WISPER lncRNA, a driver of fibrosis in the heart Phase 1a/b trial to evaluate the safety and tolerability of HTX-001 in healthy volunteers, followed by patients more...
Surescripts Expands Prior Authorization Automation, Enabling 50% More Prescribers Nationwide to Improve Medication Access for Patients in 2026
Prescribers Helped Save Patients $19.7 Million with Real-Time Prescription Benefit Since JanuaryARLINGTON, Va.--(BUSINESS WIRE)--#HealthIT--Surescripts®, the nation’s leading health intelligence network, released new data illustrating significant impact of solutions, including Prior Authorization Automation and Real-Time Prescription more...
Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures
New preclinical findings demonstrate elunetirom’s direct effects on key gene programs that drive mitochondrial biogenesis, ATP production, and neuroplasticity in neuronal cultures Topline data anticipated from Phase 2 AMPLIFY-BD study in adjunctive bipolar depression in more...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
Pivotal Phase III trial authorized to proceed in every region where IntraBio submitted regulatory applications: the U.S., U.K., EU, and Switzerland Twelve multinational clinical trial sites are now being activated, with recruitment to begin immediately more...
Leading NCI-Designated Cancer Centers Across the Country Leverage ConcertAI’s CancerLinQ to Support Personalized, Evidence-Based Quality Care
URochester Medicine Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center are among the leading institutions using the platform to drive actionable insights and advance quality initiativesCAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI®, the real‑world healthcare intelligence company more...
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its more...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis’ next-generation GEMS AI more...
The Foundation for the National Institutes of Health Announces Recipients of the Deeda Blair Research Initiative for Disorders of the Brain
NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health (FNIH) announces three new recipients of awards given by the Deeda Blair Research Initiative for Disorders of the Brain. The awards recognize clinician-scientists who more...
FDA Accepts sNDA and Grants Priority Review to AQNEURSA® for Ataxia-Telangiectasia
Pivotal Phase III Trial Meets All Primary and Key Secondary Endpoints with High Statistical Significance Levacetylleucine Could Become the First-Ever FDA-Approved Treatment for Ataxia-Telangiectasia FDA accepts sNDA for AQNEURSA® (levacetylleucine) for Ataxia-Telangiectasia — a rare, more...
Quantum Health Recognizes Clients for Excellence in Healthcare Innovation and Member Experience at Quantum Health Connect 2026
Celebrating leading employers transforming the healthcare experience for their employeesDUBLIN, Ohio--(BUSINESS WIRE)--Quantum Health, the leading healthcare navigation company, today announced the winners of its annual client awards at Quantum Health Connect 2026, recently held in more...
Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting
ST-01 demonstrated statistically significant and durable pain reduction in men with chronic scrotal content pain at the 70 mg/ml dose compared to standard of careVANCOUVER, British Columbia--(BUSINESS WIRE)--#AUA26--Sustained Therapeutics, Inc. (“Sustained Therapeutics” or the “Company”), more...
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare more...
Nourish Raises $100M Series C to Reverse Chronic Disease with AI-Native Metabolic Clinic
NEW YORK--(BUSINESS WIRE)--Nourish, the country’s largest dietitian-led metabolic health clinic, today announced its $100 million Series C, bringing total funding to $215 million. The round was led by Menlo Ventures, with participation from Thrive Capital, more...
EndoQuest Advances Multicenter PARADIGM Trial with Completion of Procedures at Baylor St. Luke’s Medical Center
Clinical progress expands to Baylor St. Luke’s with robotic endoscopic submucosal dissection procedures performed by Dr. Mohamed Othman and Dr. Tara KeihanianHOUSTON--(BUSINESS WIRE)--EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced more...
DNAnexus Scales AI-Driven Capabilities
17-Year Multiomics Pioneer Powers Next Era of Precision HealthMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--#AIInnovation--Today, DNAnexus signals a bold new chapter in AI-powered precision health with several new product innovations and solution packages that extend its position as more...
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of more...